SHERRYL ROSEN: Open Payments
NPI 1164441622 · LYNN, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,980 in 134 payments from 15 companies in 2025. Trend: 2023 $2,167 · 2024 $1,001 · 2025 $2,980
Food & beverage: $2,980
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $558 |
| ABBVIE INC. | 28 | $480 |
| Lundbeck LLC | 11 | $331 |
| Neurocrine BioSciences, Inc. | 11 | $293 |
| Janssen Pharmaceuticals, Inc | 9 | $289 |
| Teva Pharmaceuticals USA, Inc. | 11 | $267 |
| Alkermes, Inc. | 10 | $205 |
| E.R. Squibb & Sons, L.L.C. | 11 | $195 |
| Otsuka America Pharmaceutical, Inc. | 5 | $110 |
| Indivior Inc. | 3 | $79 |
Products named: CAPLYTA, VRAYLAR, REXULTI, INGREZZA, INVEGA SUSTENNA, ARISTADA, COBENFY, AUSTEDO XR.
Industry payments across MA — which companies pay providers there.
